Ovarian low-grade serous carcinoma: A comprehensive update

被引:63
作者
Diaz-Padilla, Ivan [1 ,2 ]
Malpica, Anais L. [3 ]
Minig, Lucas [4 ]
Chiva, Luis M. [5 ]
Gershenson, David M. [6 ]
Gonzalez-Martin, Antonio [7 ]
机构
[1] Univ Toronto, Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada
[2] Hosp Univ Madrid, Ctr Integral Oncol Clara Campal, Div Med Oncol, Madrid, Spain
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Hosp Univ Madrid, Ctr Integral Oncol Clara Campal, Gynecol Oncol Program, Dept Gynecol & Obstet, Madrid, Spain
[5] MD Anderson Canc Ctr, Dept Gynecol Oncol, Madrid, Spain
[6] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[7] Div Med Oncol, MD Anderson Canc Ctr, Madrid, Spain
关键词
Serous ovarian cancer; Low-grade; RAS; MEK inhibitors; Cytoreductive surgery; QUALITATIVE AGE INTERACTIONS; ACTIVATED PROTEIN-KINASE; PHASE-II; NEOADJUVANT CHEMOTHERAPY; MUTATIONAL ANALYSIS; CLINICAL BEHAVIOR; BRAF MUTATION; CANCER; EXPRESSION; STAGE;
D O I
10.1016/j.ygyno.2012.04.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian low-grade serous ovarian carcinoma (OvLGSCa) comprises a minority within the heterogeneous group of ovarian carcinomas. Despite biological differences with their high-grade serous counterparts, current treatment guidelines do not distinguish between these two entities. OvLGSCas are characterized by an indolent clinical course. They usually develop from serous tumors of low malignant potential, although they can also arise de novo. When compared with patients with ovarian high grade serous carcinoma (OvHGSCa) patients with OvLGSCa are younger and have better survival outcomes. Current clinical and treatment data available for OvLGSCa come from retrospective studies, suggesting that optimal cytoreductive surgery remains the cornerstone in treatment, whereas chemotherapy has a limited role. Molecular studies have revealed the preponderance of the RAS-RAF-MAPK signaling pathway in the pathogenesis of OvLGSCa, thereby representing an attractive therapeutic target for patients affected by this disease. Improved clinical trial designs and international collaboration are required to optimally address the unmet medical treatment needs of patients affected by this disease. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:279 / 285
页数:7
相关论文
共 73 条
[61]   The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths [J].
Siegel, Rebecca ;
Ward, Elizabeth ;
Brawley, Otis ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (04) :212-236
[62]   Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation [J].
Singer, G ;
Stöhr, R ;
Cope, L ;
Dehari, R ;
Hartmann, A ;
Cao, DF ;
Wang, TL ;
Kurman, RJ ;
Shih, IM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (02) :218-224
[63]   Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor) [J].
Singer, G ;
Shih, IM ;
Truskinovsky, A ;
Umudum, H ;
Kurman, RJ .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2003, 22 (01) :37-41
[64]   Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma [J].
Singer, G ;
Oldt, R ;
Cohen, Y ;
Wang, BG ;
Sidransky, D ;
Kurman, RJ ;
Shih, IM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (06) :484-486
[65]   Comparison of Human Papillomavirus In Situ Hybridization and p16 Immunohistochemistry in the Detection of Human Papillomavirus-Associated Head and Neck Cancer Based on a Prospective Clinical Experience [J].
Singhi, Aatur D. ;
Westra, William H. .
CANCER, 2010, 116 (09) :2166-2173
[66]   IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer [J].
Spentzos, Dimitrios ;
Cannistra, Stephen A. ;
Grall, Franck ;
Levine, Douglas A. ;
Pillay, Kamana ;
Libermann, Towia A. ;
Mantzoros, Christos S. .
ENDOCRINE-RELATED CANCER, 2007, 14 (03) :781-790
[67]   2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer Report From the Fourth Ovarian Cancer Consensus Conference [J].
Stuart, Gavin C. E. ;
Kitchener, Henry ;
Bacon, Monica ;
duBois, Andreas ;
Friedlander, Michael ;
Ledermann, Jonathan ;
Marth, Christian ;
Thigpen, Tate ;
Trimble, Edward .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (04) :750-755
[68]  
Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
[69]   Adjuvant chemotherapy for early-stage ovarian cancer:: Review of the literature [J].
Trope, Claes ;
Kaern, Janne .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) :2909-2920
[70]   Ovarian cancer is a heterogeneous disease [J].
Wang, V ;
Li, C ;
Lin, M ;
Welch, W ;
Bell, D ;
Wong, YF ;
Berkowitz, R ;
Mok, SC ;
Bandera, CA .
CANCER GENETICS AND CYTOGENETICS, 2005, 161 (02) :170-173